The imperative to recognize health as the greatest asset a country can have and a key driver of productivity and economic growth was the focus of the 1st SFEE Summit roundtable entitled “The Evolution of Pharma(R) – What’s Next and What Brings Value”. “.
The 1st SFEE Summit was attended by important actors of the Greek healthcare ecosystem, including the Greek government, the Ministry of Health and international industry leaders and experts.
The discussion focused on the evolution of the pharmaceutical industry and the revolution it has brought to national healthcare systems through sustainable solutions and innovative discoveries, while emphasizing the need for synergies across the ecosystem to address future challenges. in the health sector.
THE Khalid Ismail, Roche Pharma International’s Director of Healthcare System Development and Access noted during his speech that: “With more than 3 billion people worldwide living with chronic disease, we know that national health systems are not designed to manage this increasing demand,” he said, adding: “Demographic changes, an aging population and an increasing burden of disease in the coming years will respond to the challenges of today and the future.” will require transformation and additional investment in national health systems to make them sustainable.”
In the continuation of his speech, he emphasized that: “To address the current situation, we must recognize that it is important to see health care spending for what it really is—an investment in the better health and economic well-being of nations. Every dollar invested in healthcare has the potential to return $2-4 to national economies. An example of this is the first results of a recent study conducted by Roche together with the WifOR Institute, the world’s leading economic research institute, in Germany, and it is estimated that in 2023 a small part of Roche’s portfolio will generate more than $170. Millions in economic value for the German economy by keeping people in work, increasing productivity and enabling them to continue contributing to society as a whole.”
Khalid Ismail also emphasized the need to implement frameworks for evaluating health innovations in terms of value to patient outcomes, health system efficiency, and impact on the national economy (such as increased productivity and informal care). The need for an integrated access system covering all stages of the disease, from early detection and early treatment to patient compliance, particularly states that: “Preliminary studies estimate that the economic impact has led to increased productivity Treatment of early breast cancer is 2-3 times more than treatment of metastatic breast cancer within 10 years.
Concluding his speech, he noted that we should focus on reducing waste and increasing the efficiency of the health care system. An example is subcutaneous preparations that are administered more quickly and free up valuable clinical time. Another example is the successful implementation of the “HOME” program by the Agios Savvas General Cancer-Oncology Hospital in Greece, where more than 100 patients receive their oncology treatment at home (intravenous and subcutaneous). It is a great example of private and public sector cooperation.
At the roundtable on “Pharma (R) Evolution – What’s Next and What Brings Value”, Deputy Prime Minister Athanasios Kontogiorgis, IQVIA’s EMEA Thought Leadership Director Aurelio Arias, Vintura Partner Kasper Paardekuoper, SFEE Vice President and MSD- Agata Jakoncic, CEO for Greece, Cyprus and Malta, Nikos Dedes, Secretary General of the Greek Patients Association and Khaled Ismayil, Director of Roche’s Pharma International Health System Shaping & Access. The discussions were moderated by Star TV presenter Giorgos Evgenidis.